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Radiotherapy (RT) is a common treatment for localised prostate cancer, but can cause important side effects. The therapeutic efficacy
of RT can be enhanced by pharmacological compounds that target specific pathways involved in cell survival. This would elicit a similar
therapeutic response using lower doses of RT and, in turn, reducing side effects. This study describes the antitumour activity of the
novel Akt inhibitor 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one (Palomid 529 or P529) as
well as its ability to decrease radiation-activated phospho-Akt (p-Akt) signalling in a prostate cancer model. P529 showed a potent
antiproliferative activity in the NCI-60 cell lines panel, with growth inhibitory 50 (GI50) o35mM. In addition, P529 significantly
enhanced the antiproliferative effect of radiation in prostate cancer cells (PC-3). Analysis of signalling pathways targeted by P529
exhibited a decrease in p-Akt, VEGF, MMP-2, MMP-9, and Id-1 levels after radiation treatment. Moreover, the Bcl-2/Bax ratio was
also reduced. Treatment of PC-3 tumour-bearing mice with 20mgkg
 1 P529 or 6Gy radiation dose decreased tumour size by 42.9
and 53%, respectively. Combination of both treatments resulted in 77.4% tumour shrinkage. Decreased tumour growth was due to
reduced proliferation and increased apoptosis (as assessed by PCNA and caspase-3 immunostaining). Our results show the
antitumour efficacy of P529 alone, and as a radiosensitiser, and suggest that this compound could be used in the future to treat
human prostate cancer.
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Chemotherapy and radiotherapy (RT) are regular treatments to
decrease tumour burden and ameliorate tumour-related symp-
toms. However, current regimes are not curative in most cases,
and, in general terms, cancer mortality rates have not decreased
significantly in recent years (Jemal et al, 2008). This situation has
prompted many researchers and companies to develop novel
compounds with a higher and more selective antitumour activity.
Our study using Palomid P529 (P529) (Paloma Pharmaceuticals,
Jamaica Plain, MA, USA) has been focused on prostate cancer, the
most common malignancy in male subjects, affecting more than
10% of men over 65 years (Jemal et al, 2008). The choice of a
therapeutic modality for localised prostate cancer is often
dependent on the patient’s age, health, lifestyle, and perceived
chances for cure and potential complications. Radiotherapy is
applied in localised prostate tumours with a curative intention.
Dose increase has been associated to higher control rates. Never-
theless, high dose of radiation may have important side effects,
such as impotence, urinary dysfunctions, and rectal symptoms
(Baxter et al, 2005). New therapeutic strategies are needed as well
to improve the efficacy of RT in radioresistant patients. The use of
drugs with low toxicity that may work as radiosensitisers could
solve these problems by reducing radiation dosage while achieving
similar therapeutic efficacy, thus improving the therapeutic ratio.
Some emerging candidate radiosensitisers for prostate cancer are
2-methoxyestradiol (Casarez et al, 2007) and genistein (Raffoul
et al, 2006), two low toxic compounds with both antiangiogenic
and antitumour properties that act synergistically to enhance the
effect of RT in animal models of prostate cancer.
In this study, we have used the novel compound 8-(1-Hydroxy-
ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one
(Palomid 529, or P529) that has been recently shown to target
Akt/mTOR pathways (Xue et al, 2008). This drug is a derivative
of 3-hydroxy dibenzo[b,d]pyran-6-one, which was previously
described to share structural similarities with the potent anti-
angiogenic and antitumour compound 2-methoxyestradiol, and to
exhibit selective antiproliferative activity for endothelial cells
(Schmidt et al, 2003). Recently, benzochromenones were reported
to differentially suppress the growth of certain tumour cell lines
(Dai et al, 2007). In addition, P529 showed to reduce tumour
growth, angiogenesis, and vascular permeability in an in vivo
model of glioblastoma (Xue et al, 2008).
Our hypothesis was that as P529 inhibits the Akt pathway
(Xue et al, 2008), which is critically involved in radioresistance
(McKenna and Muschel, 2003; Cheng et al, 2006) and lacks in vivo
toxicity (Xue et al, 2008), the use of this drug would be an excellent
Revised 20 January 2009; accepted 22 January 2009; published online 24
February 2009
*Correspondence: Dr A Calvo, Division of Oncology, Center for Applied
Medical Research (CIMA). University of Navarra. Avda. Pio XII, 55. 31008
Pamplona, Spain; E-mail: acalvo@unav.es
5These authors contributed equally to this work
British Journal of Cancer (2009) 100, 932–940
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
snovel candidate to enhance the effect of RT in prostate cancer.
Here, we show that, indeed, P529 potentiates the effect of RT in the
aggressive prostate cancer cell line, PC-3, mainly through the
blockade of p-Akt activation, but also through the alteration of
other cancer-related pathways involving MMP-2, MMP-9, Id1, and
vascular endothelial growth factor (VEGF). Moreover, we show
that P529 enhances the antitumour effect of RT in vivo by reducing
the proliferation rates and promoting apoptosis.
MATERIALS AND METHODS
NCI cell growth inhibitory screening
Palomid 529 (P529) was provided from Paloma Pharmaceuticals
Inc. The ability of P529 in inhibiting cell growth proliferation was
tested in the NCI-60 tumour cells panel. The antitumour effect was
tested by the NCI core facility, following NCI protocols publicly
available at the website: http://dtp.nci.nih.gov/docs/compare/com-
pare_methodology.html#specon. Briefly, cells were grown in RPMI
1640 medium containing 5% foetal bovine serum and 2mM
L-glutamine, and then inoculated into 96-well microtitre plates
in 100ml at plating densities ranging from 5000 to 40000 cells per
well, depending on the doubling time of individual cell lines. After
24h, two plates of each cell line were fixed in situ with TCA, to
represent a measurement of the cell population for each cell line at
the time of drug addition (time zero (Tz)). P529 was applied at
different concentrations (solubilised in DMSO). Following drug
addition, the plates were incubated for an additional 48h. For
adherent cells, the assay was terminated by the addition of cold
TCA. The supernatant was discarded, and the plates were washed
five times with tap water and air-dried. Sulforhodamine B (SRB)
solution (100ml) at 0.4 % (w/v) in 1% acetic acid was added to each
well, and plates were incubated for 10min at room temperature.
After staining, unbound dye was removed by washing with 1%
acetic acid. Bound stain was subsequently solubilised with 10mM
trizma base, and the absorbance was read on an automated plate
reader at a wavelength of 515nm. For suspension cells, the
methodology was the same except that the assay was terminated by
fixing settled cells at the bottom of the wells by gently adding 50ml
of 80% TCA. Using the seven absorbance measurements (Tz,
control growth, (C), and test growth in the presence of drug at the
five concentration levels (Ti)), the percentage growth was
calculated at each of the drug concentrations levels. Percentage
growth inhibition was calculated as follows:
½ðTi   TzÞ=ðC   TzÞ  100forconcentrationsforwhichTi4= ¼ Tz
½ðTi   TzÞ=Tz  100forconcentrationsforwhichTioTz:
Data are shown as growth inhibition of 50% (GI50), which was
calculated from ((Ti Tz)/(C Tz)) 100¼50.
Cell growth inhibition of human umbilical vascular
endothelial cell (HUVEC) and PC-3 cells
As dibenzo[b,d]pyran-6-one derivatives have been shown to
inhibit very efficiently endothelial cell growth and the NCI
60 tumour cell panel did not include any endothelial cell type,
we tested the antiproliferating effect of P529 on HUVECs by MTT
assays. In addition, MTT was also used to confirm the antigrowth
effect of P529 in PC-3 cells.
Human umbilical vascular endothelial cells and the required
media complements were purchased from Cambrex Bio Science
Walkersville Inc (Walkersville, MD, USA). Growth and main-
tenance of the cultures were carried out as described by the
manufacturer. PC-3 cells were cultured in RPMI 1640 medium,
supplemented with 10% foetal clone III, and 1% penicilin–
streptomycin (all from Invitrogen, Carlsbad, CA, USA). Cultures
were incubated at 371C in a humidified 5% CO2 incubator.
Proliferation assays for HUVECs were carried out by seeding the
cells in 96-well plates at a density of 1000 cells per well. Following a
24-h plating period, cells were cultured for another 24h in 0.5%
serum before being treated with P529 (at 500nM)i nt h ep r e s e n c e
of 100ngml
 1 VEGF. Upon P529 treatment (for 24 and 96h),
proliferation was determined with the MTT Cell Proliferation Kit I
(Roche, Mannheim, Germany), according to the manufacturer’s
recommendations. For PC-3 cells, the assay was performed as
follows: 1000 cells were plated in 96-well plates and treated with
P529 for 48h. Cell proliferation rates were determined with the MTT
assay as well. Readings were performed at 540/690nm in the SunRise
ELISA plate reader (Tecan Austria GmbH, Salzburg, Austria).
Effect of P529 on colchicine binding to tubulin
The method was performed according to earlier publications
(Ma et al, 2007). Each 0.5ml reaction contained 0.1M MES (pH 7.0
with NaOH in 1M stock solution), 0.5mM MgCl2,1mM of tubulin
[
3H]colchicine (5mM), and the indicated concentration of different
drugs (1 and 5mM combretastatin A-4-phosphate (CA4P); 5 and
50mM 2-methoxyestradiol (2ME2); 5 and 50mM P529). As negative
controls, two samples were used: one without tubulin (a blank) and
another with tubulin but without inhibitor. Tubulin was added and
incubated at 371C for 120min in darkness. Reaction mixtures were
then added to 1ml microspin Sephadex G-50 (superfine) columns
and processed by centrifugal gel filtration at room temperature.
The filtrate was collected, and radioactivity was determined by
liquid scintillation counting, which allowed the calculation of a
molar ratio of drug bound to tubulin for each experiment. The
radioactivity was measured – in counts per minute (CPM) – for
each sample. Data were shown as percentage of inhibition
(% inhibition), which was calculated from CPM values as follows:
%inhibition ¼½ ð CPMtubulin   CPMsampleÞ=ðCPMtubulin
  CPMblankÞ  100:
Tubulin polymerisation assay
The assay was conducted as described previously (Hamel, 2003).
Reaction mixtures contained 0.8M monosodium glutamate,
10mM tubulin, and different concentrations of P529. Tubulin
was preincubated for 15min at 301C, and samples were chilled
on ice. Guanosine-50-triphosphate (GTP) (0.4mM) was added,
followed by a temperature jump to 371C to initiate tubulin poly-
merisation, which was measured over time at 350nm in a
temperature-controlled recording spectrophotometer for 20min.
Tubulin polymerisation was followed turbidimetrically at 350nm
in Gilford model 250 spectrophotometer (Gilford Instruments
Laboratories, Oberlin, OH, USA) equipped with electronic
temperature controllers. 2ME2 was used as positive control.
Radiation exposure
PC-3 cells (5 10
4 cells per well) were irradiated at room
temperature using 15MeV electrons (Primus Linear Accelerator,
Siemens, Erlangen, Germany) at doses of 2, 4 or 8Gy. Non-
irradiated controls were handled identically to the irradiated cells
with the exception of the radiation exposure. After irradiation,
cultures were kept at 371C and 5% CO2 in an incubator.
Proliferative and clonogenic assay after radiation
To investigate the effect of P529 on cancer cells in response to
radiation, proliferation, and clonogenic assays were performed.
A total of 50000 PC-3 cells per well were plated (in triplicate) into
6-well plates. After 24h, cells were treated with 2mM P529. One day
later, cells were irradiated according to the described protocol.
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sAfter 24h of irradiation, cells were detached from the Petri dishes
with Trypsin-EDTA (Cambrex Bio Science, Verviers, Belgium),
resuspended in PBS, and counted in a Neubauer chamber with
diluted Trypan Blue (Sigma-Aldrich Inc., St Louis, MO, USA) 1:1.
Colony formation assays were performed right after, by plating
500 cells per well into 100mm culture dishes, in triplicates.
After 12-day incubation at 371C and 5% CO2, cells were fixed
with formaldehyde and stained with 2% crystal violet. The
number of colonies was then counted and the surviving fraction
was normalised to the surviving fraction of the corresponding
control.
Total protein extraction and western blot
Whole cell pellets were collected 24-h post-irradiation along with
the corresponding non-irradiated control groups. Cells were
detached from the flasks using Trypsin-EDTA (Cambrex Bio
Science), collected by centrifugation and lysed with a lysis buffer
(RIPA: 10mM Tris pH 7,4; 150mM NaCl; 1% Triton X-100; 1%
deoxycholate; 0.1% SDS; 5mM EDTA). Extracts were aliquoted and
stored at  801C for subsequent western blot analyses. Protein
concentrations were determined with the BCA Protein Assay Kit
(Perbio, Rockford, IL, USA). In all, 20mg protein extracts were run
through NuPAGE 4–10% Bis-Tris gels (Invitrogen). Electro-
phoresis was monitored using dual color Precision Plus Protein
Standards (BioRad, Hercules, CA, USA). Proteins were transferred
to polyvinylidene difluoride membranes (Bio-Rad, Richmond,
CA, USA). Membranes were blocked with 5% non-fat dry milk in
TBS-Tween (1  TBS: 0.05M Tris-HCl, 0.5M NaCl, pH¼7.36;
0.1% Tween-20), and incubated at the recommended dilution with
the following antibodies: rabbit anti-Bcl-2 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), rabbit anti-Bax (Santa Cruz
Biotechnology), mouse anti-b-actin (Sigma), rabbit anti-Akt (Cell
Signaling Technology, Danvers, MA, USA), rabbit anti-phospho-
Akt (Cell Signaling Technology), rabbit anti-MMP-2 (Labvision,
Fremont, CA, USA), rabbit anti-MMP-9 (Sigma), rabbit anti-VEGF
(Santa Cruz Biotechnology), rabbit anti-Id-1 (BioCheck, Foster
City, CA, USA). Membranes were then incubated with one of the
following secondary antibodies (depending on the species of the
primary antibody): goat antimouse IgG (Santa Cruz Biotechno-
logy) or goat antirabbit IgG (Santa Cruz Biotechnology). Immuno-
blots were developed with the chemiluminescence detection
system Lumi-Light PLUS (Roche), exposed to Hyperfilm ECL
(Amersham) and developed with an AGFA automated X-ray film
processor.
Animals and therapeutic regimes
Male athymic nude mice were purchased from Harlam (UK).
1 10
6 PC-3 cells were injected s.c. mixed with Matrigel (Becton
Dickinson Labware, Bedford, MA, USA) in a final 0.2-ml injection
volume. Mice were randomly divided into four groups (six mice
per group): (a) controls; (b) treated s.c. with 20mgkg
 1 P529 every
3 days; (c) Treated with RT (a single dose of 6Gy, 1 week after cell
injection); (d) combination of P529 and radiation, following
similar regimes as described above. The radiation was localised
to the tumour. Tumour width (W) and length (L) were
measured once a week with a caliper. Tumour volume was
calculated as follows: volume (mm
3)¼0.5 W
2 L. Irradiation
of mice was carried out 1 week after implantation of the cells,
using a single dose of 6Gy, with a Primus Linear Accelerator
(Siemens). Mice were killed 4 weeks after cell injection by
inhalation of CO2, and tumour tissues were dissected and then
processed for histology. All mice were treated in accordance with
the guidelines for the Animal Care Ethics Commission of our
institution (University of Navarra) under an approved animal
protocol.
Histology, immunohistochemistry, and quantification of
proliferation and apoptosis in tumours
Tissues were fixed in 10% formalin, embedded in paraffin, and
sectioned (5-mm thickness). Slides were stained with H&E and
Masson’s trichrome. For proliferation and apoptosis analyses,
immunohistochemistry for PCNA and active caspase-3 was
conducted as follows: slides were deparaffinised and incubated for
10min with 3% H2O2 in water to quench the endogenous peroxidase
activity. An antigen retrieval method was used for the detection of
PCNA. Tissues were incubated with 5% normal rabbit serum in TBS
(0.05M Tris-HCl, 0.5M NaCl, pH¼7.36) for 30min at room
temperature. Dilution of the primary antibodies was as follows:
1:100 for mouse monoclonal anti-PCNA (M0879, DakoCytomation
Denmark A/S, Glostrup, Denmark) and 1:200 for rabbit polyclonal
anti-active caspase-3 (Cell Signaling). The indirect avidin–biotin–
peroxidase method was applied, using the appropriate secondary
antibodies, for 30min at room temperature. The EnVision (K4007,
Dako) signal enhancement system was used to develop the bound
antibodies. Sections were counterstained with Harris haematoxylin,
dehydrated and mounted. For quantifications, 30 random images
( 400) per experimental group were captured with a microscope
(Leica, Wetzlar, Germany) equipped with the Analysis software. The
number PCNA- and caspase-3-positive cells present in the reference
area was counted and divided by the total number of cells included
in the reference area.
Statistical analysis
An ANOVA test was used when appropriate to determine
significant differences between treatment groups. Statistical
significance was considered at the 0.05 and 0.01 levels.
RESULTS
P529 inhibits cell growth of a broad spectrum of cancer cell
lines
The cell growth inhibitory potential of P529 was first tested in the
NCI 60 Cell Screen (Developmental Therapeutics Programe
NCI/NIH). P529 inhibited cell growth of virtually all the cell lines
tested, with a GI50 lower than 35mM. The GI50 values were
variable: 2–34mM for leukaemia and non-small cell lung cancer;
6–24mM for melanoma, colon and ovarian cancers; 2–19mM for
central nervous system (CNS), renal, breast, and prostate cancer,
including the PC-3 cell line (Table 1). We conclude that P529 is
a novel drug with a wide potential inhibitory growth effect of
a variety of tumour types, including prostate cancer.
As we were particularly interested in prostate cancer, the growth
inhibition of P529 was further tested in the androgen-independent
prostate cell line, PC-3, by MTT assays (Figure 1A). Cells were
treated with different doses of P529 (0, 2, 5, 7, and 10mM). P529
caused a concentration dependent growth inhibition on PC-3 cells.
Doses of 2 and 7mM resulted in 30 and 60% growth inhibition,
respectively. After 48h treatment and on the basis of the MTT
assay, the GI50 value was estimated to be 5–7mM (Figure 1A).
Dibenzo[b,d]pyran-6-one derivatives have been shown to be
potent inhibitors of endothelial cell growth, thus suggesting anti-
angiogenic properties (Schmidt et al, 2003). We, therefore, analysed
the effect of P529 on HUVECs proliferation. P529 significantly
inhibited (Po0.001) control and VEGF-stimulated endothelial cell
proliferation, 96h after exposure to the drug (Figure 1B).
P529 neither affects tubulin polymerisation nor binds to
the colchicine site
One of the main mechanisms of the antitumoral drug 2ME2 is the
inhibition of tubulin polymerisation by interacting with the
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similarities between dibenzo[b,d]pyran-6-one derivatives and
2ME2 (Schmidt et al, 2003), we examined whether P529 would
bind to tubulin and whether this compound would affect tubulin
polymerisation. The displacement of 5mM [
3H]colchicine on 1mM
tubulin by P529 or positive control agents was expressed as rate of
inhibition. Inhibition rates of P529 at concentrations of 5 or 50mM
were 8 and 7%, respectively, and concentration-independent
(Table 2), thus showing a lack of binding to tubulin at the
colchicine’s site. Both positive controls, CA4P and 2ME2, showed a
pronounced concentration-dependent inhibition rates (Table 2).
The tubulin-binding assay showed that P529 did not inhibit
tubulin polymerisation (results not shown). These data show that
the mechanism of action of P529 differs from that of binding to
and inhibiting tubulin polymerisation.
Table 1 Cell growth inhibition 50 (GI50) of P529 in the NCI-60 tumor
cell lines panel
Panel/cell line GI50 (lM)
Leukemia
CCRF-CEM
HL-60(TB) 2.28
K-562 4.11
MOLT-4 32.7
RPMI-8226 21.5
SR 2.14
Non-small cell lung cancer
A549/ATCC 13.1
EKVX 22.3
HOP-62 11.2
NCI-H226 21.2
NCI-H23 15.1
NCI-H322M 34.3
NCI-H460 11.4
NCI-H522 8.84
Colon cancer
COLO 205 23.7
HCC-2998 12.1
HCT-116 10.8
HCT-15 12.9
HT29 6.04
KM12 14.2
SW-620 14.5
CNS cancer
SF-268 6.09
SF-295 12.2
SF-539 14.7
SNB-19 11.2
SNB-75 5.18
U251 12
Melanoma
LOX IMVI 22.5
MALME-3M 17.2
M14 16.4
SK-MEL-2 18.6
SK-MEL-26 14.5
SK-MEL-5 9.12
UACC-257 15.4
UACC-62 12.1
Ovarian cancer
ICROV1 14.9
OVCAR-3 12.8
OVCAR-4 12.8
OVCAR-5 24.1
OVCAR-8 9.02
SK-OV-3 13.6
Renal cancer
786-0 16.2
A496 15.9
ACHN 13.3
CAKI-1 11.2
RXF 393 5.24
SN 12C 17
TK-10 18.2
UO-31 15.5
Prostate cancer
PC-3 12.4
DU-145 18.6
Breast cancer
MCF7 6.01
NCI/ADR-RES 12.6
Table 1 (Continued)
Panel/cell line GI50 (lM)
MDA-MB-231/ATCC 14.7
HS 578T 13.3
MDA-MB-435 2.64
BT-549 17
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Figure 1 Cytotoxicity of P529 in PC-3 and HUVECs. (A) PC-3 cells
treated with different doses of P529. The GI50 was determined to be
5–7mM.( B) In HUVECs, 500nM of P529 in the presence of 100ng/ml
VEGF significantly (Po0.001) reduces cell proliferation, 96h after
administration of the drug.
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PC-3 cells
P529 has been previously shown to inhibit Akt signalling (Xue
et al, 2008). Because inactivation of the Akt-mediated pathway is a
demonstrated way to enhance the effect of RT (McKenna and
Muschel, 2003; Cheng et al, 2006), we investigated whether P529
would increase radiation-induced PC-3 cell growth inhibition.
For these experiments, we selected a dose of P529 that had a
significant antiproliferative effect on PC-3 cells. As mentioned
earlier, treatment of PC-3 cells with 2mM P529 alone resulted in
approximately 30% cell growth inhibition compared with un-
treated cells, and thus, this concentration was selected for
combination purposes. To test the effect of P529 plus radiation,
50000 PC-3 cells were plated and pretreated with 2mM P529 for
24h. Then, cells were irradiated with 0, 2, 4, and 8Gy. Proliferation
of PC-3 cells was analysed 72h post-plating. In addition, 500
treated cells were plated for a 10-day clonogenic assay. Adminis-
tration of 2mM P529 in combination with 2Gy radiation
dramatically decreased the tumour cell proliferation (Po0.001),
compared with 2Gy radiation alone (15 vs 70% cell survival,
respectively, compared with controls). Use of 2mM P529 plus 4 and
8Gy radiation also improved significantly the effect of each of the
radiation doses alone (Po0.05), although the effect was less
pronounced (Figure 2A).
In clonogenic assays, reduction of clonogenic capacity was
observed with the combination of P529 and RT vs RT alone with
4Gy (40 vs 60% survival fraction, respectively; Po0.01; Figure 2B).
Although the effect was mild, a similar result was found when
using 2Gy dose (Po0.05). No differences were observed for high
doses of radiation (8Gy; Figure 2B). These data show that pre-
treatment with low doses of P529 sensitises prostate cancer cells to
radiation-induced cell growth inhibition.
P529 inhibits the radiation-induced p-Akt activation and
decreases Bcl-2/Bax ratio in PC-3
The PI3K/Akt signalling pathway in cancer cells promotes proli-
feration, invasiveness, and angiogenesis, thus constituting a critical
cell survival mechanism. Activation of this pathway plays an
essential role in the resistance to conventional radiation treatment
(Cheng et al, 2006). The mitochondrial Bcl-2/Bax apoptotic
pathway also determines cell fate. To confirm our hypothesis that
pre-treatment of PC-3 cells with P529 might reduce radiation
resistance of cancer cells, we analysed p-Akt, total Akt, Bcl-2, and
Bax protein levels after individual or combined treatments.
Treatment of cells with 2Gy radiation increased the levels
of total Akt (Figure 3). The active form of Akt (p-Akt) was
dramatically increased by 2Gy radiation (RT; Figure 3). Strikingly,
the combination of P529þ2Gy radiation reduced the amount of
total and phosphorylated Akt below the control levels (Figure 3).
In addition, PC-3 cells treated with P529, radiation, and the
combination of both showed reduced levels of the antiapoptotic
protein Bcl-2 in comparison with controls (untreated cells). Levels
of the proapoptotic protein Bax were higher in RT- and RTþP529-
treated cells than in P529 or control cells (Figure 3). Densitometric
analysis showed that the Bcl-2/Bax ratio was reduced in cells
receiving radiation and RTþP529, compared with control or P529
treatment alone (Figure 3).
P529 inhibits radiation-induced overexpression of Id-1 and
VEGF
The overexpression of the inhibitor of differentiation-1 (Id-1) has
been related to radioresistance (Zhang and Rosdahl, 2003).
Activation of Id-1-mediated pathways leads to the overexpression
of the progangiogenic growth factor, VEGF (Ling et al, 2006). As
P529 has been previously shown to inhibit angiogenesis in vivo
(Xue et al, 2008), we analysed whether treatment of PC-3 cells with
this drug would block VEGF/Id-1-angiogenic pathways. Adminis-
tration of 2mM P529 alone did not change Id-1 levels, whereas
treatment with ionising radiation elevated Id-1 levels (Figure 4).
The RTþP529 combination treatment resulted in a reduction of
Id-1 below control levels (Figure 4). The overexpression of VEGF
by tumour cells is a good example of the induction of prosurvival
pathways induced by RT (Berse et al, 1992; Gorski et al, 1999;
Gupta et al, 2002). Another consequence of VEGF overexpression
is the activation of proangiogenic signalling cascades (includ-
ing Akt) in the endothelial cells of the tumour vascular bed
Table 2 Tubulin binding to the colchicine site assay
Sample CPM % Inhibition
Blank (no tubulin) 1159 —
Tubulin (no inhibitor) 18384 —
1mM CA4P 4288 82
5mM CA4P 1961 97
5mM 2ME2 7624 62
50mM 2ME2 3256 88
5mM Palomid 529 17036 8
50mM Palomid 529 17129 7
The assay shows displacement of 5mM [
3H]colchicine on 1mM tubulin by test agents.
Combretastatin-A4-phosphate (CA4P): a microtubule-destabilizing agent. CPM:
counts per minute.
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Figure 2 Proliferation and clonogenic assays of RT- and RTþP529-
treated cells. (A) Administration of 2Gy to PC-3 cells causes a 30% cell
growth inhibition, whereas addition of P529 to 2Gy radiation results in 85%
cell growth inhibition (Po0.001). P529 also enhances the antiproliferative
effect of 4Gy radiation (Po0.05). (B) In clonogenic assays, P529 enhances
the effect of RT with significant differences between RT and RTþP529,
when 2 and 4Gy are administered to the cells (Po0.05, and Po0.01,
respectively). *Po0.05; **Po0.01; ***Po0.001.
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P529 slightly increased VEGF levels, whereas RT resulted in a
strong VEGF induction. However, addition of P529 to RT reduced
VEGF levels (Figure 4). These data show that levels of two critical
prosurvival factors (Id-1 and VEGF), whose expression is induced
by RT, are decreased by the addition of P529.
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by P529
Matrix metalloproteases (MMPs) are involved in invasiveness and
metastasis (Cheng et al, 2006). MMP-2 and MMP-9 levels increase
in irradiated cells (Wang et al, 2000; Cheng et al, 2006). We
measured inactive pro-MMP-9 (MW¼92 KDa) and active MMP-9
(MW¼88 KDa) levels in PC-3 cells after P529, radiation, or P529
plus radiation treatments. In control and P529-treated cells, low
levels of inactive and active MMP-9 were found, whereas an
increase in the cleaved (active) form was observed after radiation
treatment. The combination of P529 with RT decreased both active
and inactive MMP-9 levels below control levels (Figure 4).
Radiation treatment increased modestly active (72kDa) MMP-2
levels. However, when radiation was combined with 2mM P529,
levels were found to be similar to those of controls or P529-treated
cells alone (Figure 4). The inactive form of MMP-2 did not change
with any of the treatments (results not shown). The above findings
indicate that P529 blocks radiation-mediated induction of MMP-2
and MMP-9.
P529 treatment reduces tumour growth and enhances the
effect of RT in vivo
Treatment of PC-3 tumour-bearing mice with P529 reduced
tumour growth to 57.1% compared with controls. Radiotherapy
(single dose of 6Gy) also resulted in a decreased tumour growth
(47.0% compared with controls; Figure 5A). Combination of both
therapies gave rise to tumours 22.6% in size with respect to
untreated mice (77.4% reduction of tumour growth; Figure 5A). No
weight loss was observed in any of the experimental groups.
Tumours from control mice were characterised by dense cellular
content and little stroma. Tumours from irradiated mice showed
large areas of cell damage characterised by cell swelling and
increased fibrosis. Tumour from P529-treated mice showed cells
with picnotic nuclei, and in some instances cytoplasmic swelling.
Tumours of mice treated with P529þRT exhibited more intense
tissue damage, characterised by tumour cell loss, cells with
picnotic nuclei, and extensive fibrosis (Figure 5B).
Proliferation and apoptotic rates were also calculated in these
tumours. In controls, 40.9±5.5% of tumour cells were PCNA-
positive (Figure 6A). Proliferation in RT-treated tumours was
significantly reduced (Po0.05) in comparison with controls.
Percentage of PCNA-positive cells in P529-treated mice was
29.1±6.1%, which did not reach statistical difference compared
with controls. Interestingly, RTþP529 treatment significantly
reduced (Po0.01) PCNA-positive cells to 17.1±12.2%. Apoptosis
was further assessed quantifying caspase-3-positive cells by
immunohistochemistry. Values for controls, RT, P529, and
RTþP529 were as follows: 3.3±0.7; 5.8±0.7; 5.6±1.6; and
8.7±1.7%, respectively. Therefore, these data showed that
exposure to radiation together with administration of P529
resulted in a significant enhancement of caspase-3-positive cells,
compared with individual therapies alone (Figure 6B).
Figure 7 depicts a summary of the proposed molecular
mechanisms targeted by P529 in PC-3 cells subjected to ionising
radiation, according to our results. Our data show that P529 acts
through several cell pathways to enhance the therapeutic effect of
radiation.
DISCUSSION
Mortality rates of advanced tumours have not decreased with
current therapeutic drugs (Jemal et al, 2008). Therefore, new
chemical compounds with a higher antitumour activity, alone or in
combination with current therapies, are urgently needed. Anti-
oestrogen compounds, such as tamoxifene or clomifene, have
shown antitumour and antiangiogenic activities. In this study, we
describe the biological activity of 8-(1-Hydroxy-ethyl)-2-methoxy-
3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one (P529), a recently
discovered drug that targets Akt, which has been shown to
inhibit tumour angiogenesis, vascular permeability, and tumour
growth, in a mouse model of glioblastoma (Xue et al, 2008). P529
is a derivative of 3-hydroxy dibenzo[b,d]pyran-6-one, which was
designed to structurally mimic the antiangiogenic drug 2-methoxy-
estradiol (2ME2)( S c h m i d tet al, 2003). 3-hydroxy dibenzo[b,d]
pyran-6-one exhibits selective antiproliferative activity for endo-
thelial cells (Schmidt et al, 2003). We have shown in this study that
P529 has a wide spectrum of antitumour efficacy in different tumour
cell lines, and significantly enhances the effect of RT in prostate
cancer both in vitro and in vivo.
The structural similarities between dibenzo[b,d]pyran-6-ones
and 2ME2, a tubulin polymerisation inhibitor that binds to the
colchicine’s site, prompted us study such putative activity of P529.
Here, we show that P529 neither binds to the colchicine’s site nor
blocks tubulin polymerisation. Hence, its mode of action is outside
of a tubulin agent, thus differing from one of the main 2ME2-
related mechanisms.
Activation of PI3K/Akt is a critical regulatory signalling pathway
involved in cell proliferation, transformation, apoptosis, and
angiogenesis (Fang et al, 2007). Hyperactivation of PI3K/Akt
confers cancer cells resistance to radiation-induced cell death
(McKenna and Muschel, 2003; Cheng et al, 2006). As P529 is a
novel Akt inhibitor (Xue et al, 2008) whose antitumour efficacy has
been proven in vivo, we hypothesised that this drug could enhance
the efficacy of RT in prostate cancer. The PC-3 cell line was used
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Figure 5 Effect of different treatment regimes in tumour-bearing mice. (A)
Tumour volume is greatly reduced in P529þRT- treated mice (77.4%
reduction). (B) Histology of tumours treated with radiotherapy (RT), P529,
and combination (Comb), compared with untreated mice (Co). An intense
fibrosis and tumour cell damage is observed in mice treated with P529 plus RT.
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et al, 2002). We have found that P529 reduces dramatically the
levels of phospho-Akt induced by radiation exposure (and, in a
lesser extent, total Akt), which confirms that Akt is a main target of
P529 in cancer cells. The Bcl-2/Bax ratio was also reduced in
RTþP529-treated cells, but the effect is likely due to RT alone, as
similar levels were found for RT and RTþP529.
Ionising radiation causes DNA breaks and induces a cellular
response that activates the tumour suppressor protein p53 (Lain
and Lane, 2003). However, in a high percentage of tumours and
cancer cells (such as PC-3), the p53 gene is functionally inactive. In
addition, upon irradiation, expression of proteins related to cell
survival pathways, such as EGF or VEGF/Id-1, are strongly induced
(Tsai et al, 2007) in a likely attempt to overcome cell stress and
reactive oxygen species (ROS) effect. Here, we present the data
supporting that the use of P529 could also block the radiation-
induced overexpression of survival factors, such as VEGF, Id-1,
MMP-2, and MMP-9. The overexpression of Id-1 in tumour cells
results in an increased cell proliferation and tumour angiogenesis
through the upregulation of VEGF (Ling et al, 2006). Id-1 also
confers tumour cells resistance to radio- and chemotherapy-
induced apoptosis through the activation of PI3K/Akt/NF-kB
signalling pathways (Ling et al, 2006; Li et al, 2007). Interestingly,
knockdown of Id-1 strongly sensitises PC-3 cells to chemotherapy-
induced cell death (Zhang et al, 2006).
Vascular endothelial growth factor is also upregulated in response
to ionising radiation (Gorski et al,1 9 9 9 ;G u p t aet al,2 0 0 2 ) .V a s c u l a r
endothelial growth factor not only induces angiogenesis, but also
stimulates tumour cell proliferation in an autocrine manner in
prostate cancer (Jackson et al, 2002). Therefore, targeting VEGF is
thought to represent a novel effective way of treating this type of
tumour (Rhee and Hoff, 2005). In our study, P529-mediated
reduction of VEGF levels is in keeping with the antiproliferative
effect of P529 on endothelial cells (HUVECs). Radiation induces
MMP-2 (Wang et al, 2000) and MMP-9 levels through PI3K/Akt/NF-
kB signal transduction pathways as well (Cheng et al, 2006), leading
to cell invasiveness. Therefore, blockade of MMPs has been
proposed as an attractive way to potentiate RT. We have shown
that P529 is able to block the activation of MMP-9 and to reduce the
levels of MMP-2 and pro-MMP-9 induced by radiation.
Importantly, our in vivo experiments have shown that P529
exerts antitumour activity and that the therapeutic efficacy of RT is
enhanced by this drug. The anticancer effect is because of a
decrease in cell proliferation with a concomitant increase in the
number of cells undergoing apoptosis. It is likely that the reduced
levels of survival signalling pathways activated by RT in P529-
treated mice (i.e., Akt, VEGF, Id-1, and MMPs) end up in a reduced
proliferation/apoptosis ratio in vivo, leading to tumour shrinkage.
We did not observe any toxic effect in mice treated with the drug
alone or in combination with RT, as previously shown in a mouse
model of glioblastoma (Xue et al, 2008).
In conclusion, our results show that the novel compound
8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]
chromen-6-one (P529) has a potent antitumour activity in a large
variety of tumour cells. Moreover, P529 enhances the effect of RT in
PC-3 prostate cancer cells. Pathways involving Akt, VEGF, Id-1,
MMP-9, MMP-2, and Bcl-2/Bax are targeted by this novel drug. The
ability to act at different pathway levels (mainly the Akt pathway),
all of them involved in the response to radiation, makes this
compound an attractive agent that might limit the possible tumour
escaping routs. Our results suggest that this novel compound could
be tested in the future in the clinic as a novel anticancer therapy to
enhance the effect of RT.
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